Exploring how immune cells function in the bone marrow of patients with acute myeloid leukemia.
Official title: Understanding mechanisms of impaired immunity in the AML bone marrow
Funded at Sloan-Kettering Inst Can Research · NIH-10949884 · Data updated 2026-11-12
This study is looking at how the immune system works in the bone marrow of people with acute myeloid leukemia (AML) to find out why important immune cells called T cells aren't able to fight the cancer effectively, with the goal of discovering better treatments that help these cells do their job.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | July 1, 2024 |
| Project end | June 30, 2029 |
| Funding year | 2024 |
| Award (this year) | $303,621 |
| NIH project number | 1K08CA293271-01 |
| Project ID | NIH-10949884 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with acute myeloid leukemia who are undergoing treatment.
✕Less likely to help
Patients with other types of leukemia or those who are not currently receiving treatment for AML may not benefit from this research.
What this research studies
This research investigates the immune system's response in the bone marrow of patients with acute myeloid leukemia (AML), a serious blood cancer. The study aims to understand why T cells, which are crucial for fighting cancer, become ineffective in this environment. By examining the interactions between cancer cells and immune cells, the researchers hope to identify factors that impair T cell activity. This knowledge could lead to improved immunotherapy strategies for treating AML.
Why it matters
Potential benefit: If successful, this research could enhance the effectiveness of immunotherapy for patients with acute myeloid leukemia.
How similar studies have gone: Previous research has shown promising results in using immunotherapy for blood cancers, indicating that this approach has potential for success.
Where this research is happening
-
Sloan-Kettering Inst Can Research
New York, United States Active
Researchers
- Principal investigator: Dewolf, Susan E — Sloan-Kettering Inst Can Research
- Study coordinator: Dewolf, Susan E
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.